XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis.
To examine the association between three x-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms (Arg(194)Trp, Arg(280)His, and Arg(399)Gln) and bladder cancer susceptibility. A comprehensive search was conducted to identify all case-control studies of XRCC1 polymorphisms and bladder cancer risk. Statistical analysis was performed with the software program Review Manage, version 4.2. A total of 10 eligible reports, including 3749 cases and 3947 controls, were identified. For Arg(194)Trp (six studies, 3091 cases, 3219 controls), no evidence indicated that individuals carrying the variant genotypes (Trp/Trp + Arg/Trp), relative to those carrying the wild homozygote Arg/Arg genotype, had a decreased risk of bladder cancer (odds ratio [OR] 0.90, 95% confidence interval [CI] 0.77 to 1.05; P = 0.17). For Arg(280)His (three studies, 2547 cases, 1784 controls), individuals with His/His+Arg/His genotypes had no significant risk of bladder cancer, compared with those with the Arg/Arg genotype (OR 0.99, 95% CI 0.55 to 1.77; P = 0.97). For Arg(399)Gln (10 studies, 3729 cases, 3927 controls), the Gln/Gln genotype carriers did not have a decreased cancer risk compared with those individuals with the Arg/Arg genotype (OR 0.95, 95% CI 0.82 to 1.10; P = 0.48). Similarly, no associations were found in the recessive and dominant modeling (Gln/Gln versus Arg/Gln+Arg/Arg: OR 0.92, 95% CI 0.80 to 1.05; P = 0.23; Arg/Gln+Gln/Gln versus Arg/Arg: OR 1.04, 95% CI 0.95 to 1.14; P = 0.36). No association was found between the polymorphisms in XRCC1 (Arg(194)Trp, Arg(280)His, Arg(399)Gln) and bladder cancer susceptibility.